Core Viewpoint - INVO Fertility, Inc. reported its second quarter 2025 financial results, highlighting a focus on expanding fertility operations and innovative service offerings while navigating a net loss from continuing operations. Financial Highlights - Revenue for Q2 2025 was $1,863,654, marking a 1% increase from $1,836,597 in Q2 2024, setting a new quarterly record for the company [7] - Consolidated clinic revenue increased by 1% to $1,832,094 compared to $1,807,921 in the previous year [7] - Total revenue from all clinics, including consolidated and equity method clinics, rose by 2% to $2,188,893 from $2,141,229 [7] - Net loss from continuing operations was $(3.2) million, compared to $(2.2) million in the prior year [7] - Adjusted EBITDA was $(587,230), a decline from $(509,623) in Q2 2024 [7][15] Operational Highlights - The company completed the divestiture of a majority stake in NAYA on June 2, 2025, allowing both INVO Fertility and NAYA to focus on their respective operations [4] - INVO Fertility expanded its service offerings to include telehealth options and Platelet-Rich Plasma (PRP) therapy at its Wisconsin clinic, enhancing patient-centered care [5][7] - The Wisconsin Fertility Institute was recognized on Newsweek's List of America's Best Fertility Clinics for 2025 [7] - A new patent for a modified version of the INVOcell device was allowed, extending intellectual property protection through 2040 [7] Management Commentary - The CEO emphasized the commitment to growth and innovation in fertility operations, highlighting the expansion of services and training support for INVOcell technology [5] - The company aims to maintain an efficient and scalable operating structure while integrating complementary revenue-generating businesses and technologies [5]
INVO Fertility Announces Second Quarter 2025 Financial Results